89 related articles for article (PubMed ID: 20579727)
1. Actions of the anti-cancer drug suberoylanilide hydroxamic acid (SAHA) on human breast cancer cytoarchitecture in silicon microstructures.
Strobl JS; Nikkhah M; Agah M
Biomaterials; 2010 Sep; 31(27):7043-50. PubMed ID: 20579727
[TBL] [Abstract][Full Text] [Related]
2. MCF10A and MDA-MB-231 human breast basal epithelial cell co-culture in silicon micro-arrays.
Nikkhah M; Strobl JS; Schmelz EM; Roberts PC; Zhou H; Agah M
Biomaterials; 2011 Oct; 32(30):7625-32. PubMed ID: 21764441
[TBL] [Abstract][Full Text] [Related]
3. The cytoskeletal organization of breast carcinoma and fibroblast cells inside three dimensional (3-D) isotropic silicon microstructures.
Nikkhah M; Strobl JS; De Vita R; Agah M
Biomaterials; 2010 Jun; 31(16):4552-61. PubMed ID: 20207413
[TBL] [Abstract][Full Text] [Related]
4. Cytoskeletal role in differential adhesion patterns of normal fibroblasts and breast cancer cells inside silicon microenvironments.
Nikkhah M; Strobl JS; Peddi B; Agah M
Biomed Microdevices; 2009 Jun; 11(3):585-95. PubMed ID: 19089620
[TBL] [Abstract][Full Text] [Related]
5. Attachment and response of human fibroblast and breast cancer cells to three dimensional silicon microstructures of different geometries.
Nikkhah M; Strobl JS; Agah M
Biomed Microdevices; 2009 Apr; 11(2):429-41. PubMed ID: 19058013
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
9. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D regulates the phenotype of human breast cancer cells.
Pendás-Franco N; González-Sancho JM; Suárez Y; Aguilera O; Steinmeyer A; Gamallo C; Berciano MT; Lafarga M; Muñoz A
Differentiation; 2007 Mar; 75(3):193-207. PubMed ID: 17288543
[TBL] [Abstract][Full Text] [Related]
11. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
12. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
Komatsu N; Kawamata N; Takeuchi S; Yin D; Chien W; Miller CW; Koeffler HP
Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
[TBL] [Abstract][Full Text] [Related]
13. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin.
ter Haar E; Hamel E; Balachandran R; Day BW
Anticancer Res; 1997; 17(3C):1861-9. PubMed ID: 9216636
[TBL] [Abstract][Full Text] [Related]
14. BRMS1 expression alters the ultrastructural, biomechanical and biochemical properties of MDA-MB-435 human breast carcinoma cells: an AFM and Raman microspectroscopy study.
Wu Y; McEwen GD; Harihar S; Baker SM; DeWald DB; Zhou A
Cancer Lett; 2010 Jul; 293(1):82-91. PubMed ID: 20083343
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
16. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Hrzenjak A; Kremser ML; Strohmeier B; Moinfar F; Zatloukal K; Denk H
J Pathol; 2008 Dec; 216(4):495-504. PubMed ID: 18850582
[TBL] [Abstract][Full Text] [Related]
17. AFM indentation study of breast cancer cells.
Li QS; Lee GY; Ong CN; Lim CT
Biochem Biophys Res Commun; 2008 Oct; 374(4):609-13. PubMed ID: 18656442
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
[TBL] [Abstract][Full Text] [Related]
19. Bioimpedance rise in response to histone deacetylase inhibitor is a marker of mammary cancer cells within a mixed culture of normal breast cells.
Srinivasaraghavan V; Strobl J; Agah M
Lab Chip; 2012 Dec; 12(24):5168-79. PubMed ID: 23108380
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
